255 related articles for article (PubMed ID: 28589434)
1. Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients.
Fondevilla Soler A; López-Guerra JL; Dzugashvili M; Sempere Rincón P; Sautbaet A; Castañeda P; Díaz JM; Praena-Fernandez JM; Rivin Del Campo E; Azinovic I
Clin Transl Oncol; 2017 Dec; 19(12):1469-1477. PubMed ID: 28589434
[TBL] [Abstract][Full Text] [Related]
2. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.
Ma L; Qiu B; Li Q; Chen L; Wang B; Hu Y; Liu M; Zhang L; Huang Y; Deng X; Xia Y; Lin M; Liu H
Radiat Oncol; 2018 Jul; 13(1):130. PubMed ID: 30016978
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience.
Mantel F; Müller E; Kleine P; Zimmermann M; Exner F; Richter A; Weick S; Ströhle S; Polat B; Höcht S; Flentje M
Strahlenther Onkol; 2021 May; 197(5):405-415. PubMed ID: 33725133
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study.
Wang D; Bi N; Zhang T; Zhou Z; Xiao Z; Liang J; Chen D; Hui Z; Lv J; Wang X; Wang X; Deng L; Wang W; Wang J; Wang C; Lu X; Xu K; Wu L; Xue W; Feng Q; Wang L
Radiat Oncol; 2019 Jun; 14(1):106. PubMed ID: 31196118
[TBL] [Abstract][Full Text] [Related]
5. Salvage radiotherapy with simultaneous integrated boost in non small-cell lung cancer patients with mediastinal relapse after surgery: a pilot study.
Nicosia L; Agolli L; Reverberi C; De Sanctis V; Marinelli L; Minniti G; Di Muzio J; Valeriani M; Osti MF
Radiat Oncol; 2018 Oct; 13(1):207. PubMed ID: 30352607
[TBL] [Abstract][Full Text] [Related]
6. Outcome and toxicity of intensity-modulated radiotherapy with simultaneous integrated boost in patients with pharyngo-laryngeal cancer.
Fondevilla Soler A; López-Guerra JL; García Fernández A; Samaniego Conde MA; Belmonte González MJ; Praena-Fernandez JM; Rivin Del Campo E; Alcaraz M; Azinovic I
Clin Transl Oncol; 2019 Jul; 21(7):881-890. PubMed ID: 30506131
[TBL] [Abstract][Full Text] [Related]
7. Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy.
Yegya-Raman N; Reyhan M; Kim S; Deek MP; Yue N; Zou W; Malhotra J; Aisner J; Jabbour SK
Pract Radiat Oncol; 2019 Jan; 9(1):e74-e82. PubMed ID: 30144583
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
Zhang Q; Cai XW; Feng W; Yu W; Fu XL
BMC Cancer; 2022 Jan; 22(1):96. PubMed ID: 35065627
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
J Radiat Res; 2021 Sep; 62(5):894-900. PubMed ID: 34260719
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
[TBL] [Abstract][Full Text] [Related]
12. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
Chen D; Menon H; Verma V; Seyedin SN; Ajani JA; Hofstetter WL; Nguyen QN; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Barsoumian HB; Erasmus JJ; Lee JH; Bhutani MS; Hess KR; Minsky BD; Welsh JW
JAMA Oncol; 2019 Nov; 5(11):1597-1604. PubMed ID: 31529018
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity.
Ristau J; Thiel M; Katayama S; Schlampp I; Lang K; Häfner MF; Herfarth K; Debus J; Koerber SA
Radiat Oncol; 2021 Feb; 16(1):23. PubMed ID: 33522923
[TBL] [Abstract][Full Text] [Related]
14. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.
Haslett K; Bayman N; Franks K; Groom N; Harden SV; Harris C; Hanna G; Harrow S; Hatton M; McCloskey P; McDonald F; Ryder WD; Faivre-Finn C
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1341-1348. PubMed ID: 33232772
[TBL] [Abstract][Full Text] [Related]
15. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
16. [Application of Simultaneous Integrated Boost Intensity Modulated Radiotherapy in Locally Advanced Non-small Cell Lung Cancer].
You J; Yang D; Li D; Jiang L; Yu R; Yu H; Xu B; Wang W; Shi A
Zhongguo Fei Ai Za Zhi; 2019 Nov; 22(11):696-701. PubMed ID: 31771738
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous integrated boost of intensity-modulated radiation therapy to Stage II-III non-small cell lung cancer with metastatic lymph nodes.
Li QS; Liang N; Ouyang WW; Su SF; Ma Z; Geng YC; Yang WG; Hu YX; Li HQ; Lu B
Cancer Med; 2020 Nov; 9(22):8364-8372. PubMed ID: 32902184
[TBL] [Abstract][Full Text] [Related]
18. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study.
Sakanaka K; Ishida Y; Fujii K; Ishihara Y; Nakamura M; Hiraoka M; Mizowaki T
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):191-201. PubMed ID: 32768158
[TBL] [Abstract][Full Text] [Related]
19. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Ning MS; Tang L; Gomez DR; Xu T; Luo Y; Huo J; Mouhayar E; Liao Z
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):70-79. PubMed ID: 28816165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
